Dry Powder Inhalers
Dry Powder Inhalers - Related Videos
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
0 Views •
Cited by 11 •
2017
The inhalation unit described herein can generate, sample for characterization, and uniformly deposit a drug aerosol in the lungs of rodents. This enables the pre-clinical determination of the efficacy and safety of drug doses deposited in the lungs; key data enabling clinical inhaled drug development.
07:55
Intratracheal Administration of Dry Powder Formulation in Mice
0 Views •
Cited by 20 •
2020
Dry powder formulations for inhalation have great potential in treating respiratory diseases. Before entering human studies, it is necessary to evaluate the efficacy of the dry powder formulation in preclinical studies. A simple and noninvasive method of the administration of dry powder in mice through the intratracheal route is presented.
04:59
Disposable Dosators Intended for Dry Powder Delivery to Mice
0 Views •
Cited by 2 •
2023
Pharmaceutical dry powder development necessitates reliable in vivo testing, often using a murine model. Device technology for accurately and reproducibly delivering dry powder aerosols to mice is restricted. This study presents disposable dosators for pulmonary drug delivery at mouse-relevant doses, aiding initial proof-of-concept research.
10:11
Whole-Body Nanoparticle Aerosol Inhalation Exposures
0 Views •
Cited by 51 •
2013
A whole-body nanoparticle aerosol inhalation exposure facility was constructed for nano-sized titanium dioxide (TiO2) inhalation toxicology studies. This system provides nano-TiO2 aerosol test atmospheres that have: 1) a steady mass concentration; 2) a homogenous composition free of contaminants; and 3) a stable particle size distribution during aerosol generation.
12:00
Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
0 Views •
Cited by 9 •
2017
This work details a step-by-step method to prepare polyphenol-rich extracts from freeze-dried berry powder. In addition, it provides a thorough description of how to use these polyphenol-rich extracts in cell culture in the presence of the peptide hormone angiotensin II (Ang II) using Vascular Smooth Muscle Cells (VSMCs).
FAQs
An inhaled breath must generate enough airflow to create turbulence inside the device. That turbulence breaks clusters of finely milled medication into smaller airborne particles, allowing a respirable fraction to move toward the airways. If inspiratory flow is inadequate, deagglomeration and transport may be reduced, which can limit how much medication reaches the lungs.
When a formulation contains larger carrier particles, airflow helps detach the milled drug from those carriers. The released drug particles can then be carried onward, while the carrier material serves a different role in the powder mixture. This separation step is important because lung delivery depends on generating the respirable fraction rather than simply dispersing the powder.
The key factors are adequate inspiratory flow, the selected device, and the patient's inhaler technique. Inspiratory flow drives powder dispersion, while device characteristics and technique influence how effectively medication becomes available for airway deposition. These variables help explain why two patients receiving comparable therapies may experience different lung delivery and clinical responses.
Unlike systems that use liquid propellants, Dry Powder Inhalers deliver medication from a dry powder formulation and use the patient's inhalation to generate the airflow needed for dispersion. This propellant-free approach supports portability and outpatient treatment, but it also makes adequate inspiratory flow especially important for effective powder deagglomeration and airway delivery.
Dry Powder Inhalers can deliver bronchodilators, corticosteroids, and combinations of these therapies. Clinically, they may be used in treatment plans for asthma and chronic obstructive pulmonary disease. The medication category matters because the device may support airway treatment with one therapy or a combined approach, depending on the prescribed respiratory treatment.
Device selection and inhaler technique directly affect lung deposition and clinical response. In outpatient care, portability and ease of use can support continued treatment, but those advantages do not replace correct operation or sufficient inspiratory flow. Choosing an appropriate device and maintaining effective technique therefore remain important parts of achieving the intended respiratory treatment outcome.